Reviva Pharmaceuticals (RVPH) Corporate presentation summary

Clinical development pipeline and market opportunities

• Brilaroxazine, a novel serotonin/dopamine modulator, is in advanced clinical development for schizophrenia, with additional potential in bipolar disorder, major depressive disorder, ADHD, PAH, IPF, psoriasis, depression, and obesity.

• Estimated market opportunities for these indications range from $8.6B (IPF) to $130B (obesity) by 2034.

Schizophrenia clinical trial results

• Brilaroxazine demonstrated significant efficacy in Phase 3 RECOVER trials, with a 10.1-point reduction in PANSS total score vs placebo (p<0.001) and early separation from placebo within a week.

• Strong efficacy was observed for negative symptoms, with a 2.0-point decrease in PANSS negative symptoms and 2.1-point decrease in Marder factor scores over 4 weeks (p<0.01).

• Durable effects were sustained over 1 year, with an 18-point decrease in PANSS total score and <1% relapse rate.

• Brilaroxazine showed broad-spectrum efficacy across symptom domains, including positive, negative, cognitive, and social symptoms.

Safety and tolerability profile

• Brilaroxazine was generally well-tolerated over 1 year, with most common TEAEs being headache, insomnia, sleep disturbance, and tremor; no drug-related serious adverse events or major safety concerns.

• Minimal metabolic, endocrine, sexual, cardiac, GI, and liver side effects; benign weight gain (1.52 kg) and decreased lipid levels.

• Significant reduction in elevated prolactin levels, maintained over 1 year.

• Low rates of extrapyramidal symptoms and akathisia.